BioXcel Therapeutics

BioXcel Therapeutics Goodwill

Delisted·Oct 8, 2026

Goodwill of BioXcel Therapeutics (BTAI) as of Nov 18, 2026.

Goodwill

-USD

Last updated:

Goodwill of BioXcel Therapeutics is 2026 - USD. Goodwill of BioXcel Therapeutics was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioXcel Therapeutics Stock analysis

What does BioXcel Therapeutics do? BioXcel Therapeutics Inc, based in New Haven, US, is a clinical stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing drugs using AI-driven re-innovation of approved product candidates. It employs 29 full-time staff and is listed on the stock market since March 8, 2018. Its key programs include BXCL501, a sublingual film for agitation treatment, and BXCL701, an immuno-oncology agent for prostate and pancreatic cancer. BioXcel Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioXcel Therapeutics stock

On Eulerpool you can find the complete historical development of Goodwill BioXcel Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's BioXcel Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioXcel Therapeutics

All Key Metrics — BioXcel Therapeutics